Bio View

Bio View OCF/Debt

The Operating Cash Flow to Debt Ratio of Bio View (BIOV.TA) as of Oct 23, 2026 is -109.45 %. In the previous year, Operating Cash Flow to Debt Ratio was -156.55 % — a change of -30.09% (higher).

OCF/Debt

-109.45 %

YoY

-30.09%

Last updated:

Operating Cash Flow to Debt Ratio of Bio View is 2025 -109.45 % . Operating Cash Flow to Debt Ratio of Bio View was 2024 -156.55 % . It decreases by -30.09% higher compared to the previous year.

The Bio View OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2019
100.28 ILS
Jan 1, 2020
54.86 ILS
Jan 1, 2021
70.46 ILS
Jan 1, 2022
23.85 ILS
Jan 1, 2023
4.36 ILS
Jan 1, 2024
-156.55 ILS
Jan 1, 2025
-109.45 ILS
The Bio View OCF/Debt history
YEAROCF/DebtYoY
-109.45 %-30.09%
-156.55 %-3,687.40%
4.36 %-81.71%
23.85 %-66.15%
70.46 %+28.45%
54.86 %-45.30%
100.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio View Stock analysis

What does Bio View do? BioView Ltd. generates revenue through the sale and servicing of its Duet automated cell diagnostic system, designed for use in cytology, cytogenetic, hematology, and pathology laboratories. The Duet system enables automated detection, classification, analysis, and counting of cells, offering unique capabilities in analyzing both cell morphology and genetic content simultaneously. Additional products include the ALLEGRO workstation for automated scanning of FISH probes without Brightfield scanning and the ACCORD workstation for semi-automated imaging of FISH in breast cancer (Her-2/Neu) analysis and FISH on tissue. These systems target medical professionals in cancer diagnosis, minimal-residual disease monitoring, prenatal and postnatal cytogenetic analyses, sperm cell studies, and rare-cell detection. The company's primary customers are laboratories specializing in cytology, cytogenetics, hematology, and pathology, including those focused on cancer diagnostics and genetic analysis. These institutions purchase the Duet system for routine diagnostic workflows and the ALLEGRO and ACCORD workstations for specialized applications such as FISH analysis in breast cancer and genetic studies. BioView Ltd. also provides ongoing servicing and support for its systems, contributing to recurring revenue streams. BioView Ltd. markets its products under the brand names Duet, ALLEGRO, and ACCORD, with the Duet system serving as the core offering for general cell analysis. The ALLEGRO and ACCORD workstations cater to niche applications in FISH-based diagnostics, particularly in oncology and genetic testing. The company's revenue is derived from direct sales of these systems to healthcare facilities and laboratories, with no mention of third-party partnerships or additional revenue streams beyond product sales and servicing. Bio View is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio View stock

Operating Cash Flow to Debt Ratio of Bio View is -109.45 % in 2025.

Operating Cash Flow to Debt Ratio of Bio View changed from -156.55 % to -109.45 %, representing a -30.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Bio View since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Bio View with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bio View

All Key Metrics — Bio View